Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 480-485

  Arias Pulido, Hugo ^a   Smith, Harriet O ^a,b   Joste, Nancy E ^a   Bocklage, Therese ^a   Qualls, Clifford R ^a   Chavez, Allison ^a   Prossnitz, Eric R ^a   Verschraegen, Claire F ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Epithelial ovarian tumors; Estrogen receptor; Immunohistochemistry; Low malignant potential tumors; Overall survival; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; ENDOCRINE TUMOR; ENDOMETRIUM TUMOR; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW MALIGNANT POTENTIAL TUMOR; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; YOUNG ADULT;

EID: 67651149472     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.045     Document Type: Article

References (34)

1. Auersperg N., Ota T., and Mitchell G.W. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int. J. Gynecol. Cancer 12 (2002) 691-703
2. Fathalla M.F. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 2 (1971) 163
3. Ho S.M. Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 73
4. Lukanova A., and Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol. Biomark. Prev. 14 (2005) 98-107
5. Yager J.D. Chapter 3: Endogenous estrogens as carcinogens through metabolic activation. J. Natl. Cancer Inst. Monographs 2000 (2000) 67-73
6. Liehr J.G. Is estradiol a genotoxic mutagenic carcinogen?. Endocr. Rev. 21 (2000) 40-54
7. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J. Natl. Cancer Inst. 90 (1998) 1774-1786
8. Gabra H., Taylor L., Cohen B.B., Lessels A., Eccles D.M., Leonard R.C., et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br. J. Cancer 72 (1995) 367-375
9. Gabra H., Watson J.E.V., Taylor K.J., Mackay J., Leonard R.C.F., Steel C.M., Porteous D.J., and Smyth J.F. Definition and Refinement of a Region of Loss of Heterozygosity at 11q23.3-q24.3 in Epithelial Ovarian Cancer Associated with Poor Prognosis. Cancer Res. 56 (1996) 950-954
10. Bardin A., Boulle N., Lazennec G., Vignon F., and Pujol P. Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr. Relat. Cancer 11 (2004) 537-551
11. Lindgren P.R., Cajander S., Backstrom T., Gustafsson J.A., Makela S., and Olofsson J.I. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol. Cell. Endocrinol. 221 (2004) 97-104
12. Pujol P., Rey J.M., Nirde P., Roger P., Gastaldi M., Laffargue F., et al. Differential Expression of Estrogen Receptor-α and -β Messenger RNAs as a Potential Marker of Ovarian Carcinogenesis. Cancer Res. 58 (1998) 5367-5373
13. Rutherford T., Brown W.D., Sapi E.V.A., Aschkenazi S., Munoz A., and Mor G.I.L. Absence of Estrogen Receptor-β Expression in Metastatic Ovarian Cancer. Obstet. Gynecol. 96 (2000) 417-421
14. Lee P., Rosen D.G., Zhu C., Silva E.G., and Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol. Oncol. 96 (2005) 671-677
15. Munstedt K., Steen J., Knauf A.G., Buch T., von Georgi R., and Franke F.E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 (2000) 1783-1791
16. Lindgren P., Backstrom T., Mahlck C.G., Ridderheim M., and Cajander S. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int. J. Oncol. 19 (2001) 31-38
17. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am. J. Obstet. Gynecol. 170 (1994) 974-979 [discussion 979-80]
18. Lachin J. Biostatistical methods (2000), John Wiley and Sons, NY 272
19. Sherman M.E., Mink P.J., Curtis R., Cote T.R., Brooks S., Hartge P., and Devesa S. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100 (2004) 1045-1052
20. Shih I.M., and Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin. Cancer Res. 11 (2005) 7273-7279
21. Chan J.K., Tian C., Monk B.J., Herzog T., Kapp D.S., Bell J., and Young R.C. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 112 (2008) 2202-2210
22. Abu-Jawdeh G.M., Jacobs T.W., Niloff J., and Cannistra S.A. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol. Oncol. 60 (1996) 301-307
23. Chien J.R., Aletti G., Bell D.A., Keeney G.L., Shridhar V., and Hartmann L.C. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell. Biochem. 102 (2007) 1117-1129
24. Wong H.F., Low J.J., Chua Y., Busmanis I., Tay E.H., and Ho T.H. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int. J. Gynecol. Cancer 17 (2007) 342-349
25. Kavanagh J.J., Hu W., Fu S., Deavers M., Moore C., Coleman R.L., et al. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors. ASCO Meeting Abstracts 25 (2007) 5582
26. Wong K.K., Lu K.H., Malpica A., Bodurka D.C., Shvartsman H.S., Schmandt R.E., et al. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol. 26 (2007) 404-409
27. Plaxe S.C. Epidemiology of low-grade serous ovarian cancer. Am. J. Obstet. Gynecol. 198 (2008) 459.e1-459.e8 [discussion 459.e8-9]
28. Carey L.A., Dees E.C., Sawyer L., Gatti L., Moore D.T., Collichio F., et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13 (2007) 2329-2334
29. Rendina G.M., Donadio C., and Giovannini M. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur. J. Gynaecol. Oncol. 3 (1982) 241-246
30. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., and Smyth J.F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. 8 (2002) 2233-2239
31. Ramirez P.T., Schmeler K.M., Milam M.R., Slomovitz B.M., Smith J.A., Kavanagh J.J., et al. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol. Oncol. 110 (2008) 56-59
32. Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R.W., et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13 (2007) 3617-3622
33. Zheng H., Kavanagh J.J., Hu W., Liao Q., and Fu S. Hormonal therapy in ovarian cancer. Int. J. Gynecol. Cancer 17 (2007) 325-338
34. Duffy M.J. Estrogen receptors: role in breast cancer. Crit. Rev. Clin. Lab. Sci. 43 (2006) 325-347